Gonyautoxin III

DB19187ExperimentalSmall molecule

Gonyautoxin III is currently under investigation in clinical trial (Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study) for the treatment of Acute Back Pain.

Mechanism: Pharmacologically active on Sodium channel protein type 4 subunit alpha and Voltage-gated sodium channel alpha subunit
Curator reviewed
Formula / weight: C₁₀H₁₇N₇O₈S · 395.35 g/mol (avg)
Also known as: (+)-gonyautoxin 3 · 11.beta.-hydroxysaxitoxin 11-sulfate · 1h,10h-pyrrolo(1,2-c)purine-9,10,10-triol, 2,6-diamino-4-(((aminocarbonyl)oxy)methyl)-3a,4,8,9-tetrahydro-, 9-(hydrogen sulfate), (3as-(3a.alpha.,4.alpha.,9.alpha.,10ar*))- 11-sulfate · 1h,10h-pyrrolo(1,2-c)purine-9,10,10-triol, 2,6-diamino-4-(((aminocarbonyl)oxy)methyl)-3a,4,8,9-tetrahydro-, 9-(hydrogen sulfate), (3as,4r,9s,10as)- · Gonyautoxin 3
Code names: GTX3

Resolves to

Compound

UNII1FFI43DL2KCAS60537-65-7

Structure

InChIKeyARSXTTJGWGCRRR-LJRZAWCWSA-NSMILES[H][C@@]12NC(=N)N[C@]11N(C[C@H](OS(O)(=O)=O)C1(O)O)C(=N)N[C@H]2COC(N)=O

Targets

P35499SCN4A

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gonyautoxin III, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account